Detalhe da pesquisa
1.
Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors.
Oncologist
; 28(6): 479-485, 2023 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36994847
2.
Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.
Neuroendocrinology
; 112(3): 298-310, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-33940581
3.
Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues.
Oncologist
; 26(7): e1171-e1178, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097784
4.
Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients?
BMC Cancer
; 21(1): 580, 2021 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34016080
5.
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
Oncologist
; 24(8): e662-e670, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30651397
6.
Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Review and a Single Center Experience.
Lung
; 196(5): 577-581, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30167840
7.
Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy.
BMC Cancer
; 17(1): 602, 2017 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28854908
8.
Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis.
J Surg Oncol
; 114(4): 451-5, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27238300
9.
Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
Neuroendocrinology
; 102(1-2): 18-25, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25824001
10.
Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
Cancer Lett
; 596: 216993, 2024 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38801884
11.
Deregulation of Wnt/ß-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors.
Carcinogenesis
; 34(5): 953-61, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23354304
12.
Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
Oncologist
; 18(1): 46-53, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23263288
13.
hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors.
Cancers (Basel)
; 14(4)2022 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35205614
14.
68Ga-DOTATATE PET/CT: The Optimum Standardized Uptake Value (SUV) Internal Reference.
Acad Radiol
; 29(1): 95-106, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34756348
15.
Management of Large Cell Neuroendocrine Carcinoma.
Front Oncol
; 11: 653162, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34513663
16.
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
J Gastrointest Cancer
; 52(1): 212-221, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32146619
17.
PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors.
Cells
; 10(5)2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34065268
18.
Benchmarks for Academic Oncology Faculty.
JCO Oncol Pract
; 17(3): e440-e444, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32997608
19.
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors.
NPJ Precis Oncol
; 5(1): 74, 2021 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34354225
20.
Primary Metastatic Small Intestinal Carcinoid Tumor Without Carcinoid Syndrome.
Oncology (Williston Park)
; 29(10): 755-6, 759, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26470900